Global drug launches always pose unique challenges, but are often even greater when in rare disease. The combination of higher prices, complex therapies, smaller patient populations, unique health systems and public health priorities likely mean you’ll need more data and additional supportive evidence to meet the needs of international markets.
An early access program is often a suitable route to preparing companies to meet these market access challenges but it is important to plan and execute this thoroughly, aligning program objectives to commercial goals and strategy as well as patient needs, otherwise you could be missing the opportunity to gain valuable insights, relevant patient-experience data and impact on launch.
We use our expertise and program design architecture to score countries on attributes such as:
- Market opportunity
- Size of patient population
- MAP reimbursement considerations
- Impact on other markets
- Presence of key stakeholders and competitors
- Feasibility to execute
- Regulatory considerations
- Existing capabilities/infrastructure
- MAP vendor capabilities
The result is a roadmap for launch preparing you to identify those countries where you are most likely to be successful, well in advance of your global launch.